Verdiva cancels GLP-1 switching trial, citing market evolution
The well-financed obesity biotech drops a study designed around patients moving off existing incretin therapy.
PR
By Priya Raman · Science Reporter
Oct 14 10:13 ETSource: Fierce Biotech
The wire
- 01Fierce Biotech reports Verdiva has axed its GLP-1 switching trial, with the company attributing the decision to market evolution.
- 02Switching studies are how late entrants try to carve share from semaglutide and tirzepatide, so a cancellation signals a shifting commercial calculus in obesity.
- 03Details on the trial's stage, enrollment and what replaces it in Verdiva's pipeline were not laid out in the report.
From the source
Read at fiercebiotech.comDeep-pocketed Verdiva axes GLP-1 switching trial over ‘market evolution’
